



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug
Administration Silver Spring
MD 20993

MEMORANDUM

Date: 10th July, 2017

To: **Biologics License Application Submission Tracking Number # 125428/0**

From: Varsha Garnepudi 

Division of Biological Standards and Quality Control (DBSQC)

Office of Compliance and Biologics Quality (OCBQ)

Center for Biologics Evaluation and Research (CBER)

Food and Drug Administration (FDA)

Through: William M. McCormick, Ph.D., Director, 

DBSQC/OCBQ/CBER/FDA

Subject: **Addendum to resubmission dated February 7th 2017 in response to CBER's complete response letter dated 16th November 2016: Review of Lot Release Protocol Templates for Drug Substance and Drug Product of Biologics License Application for Hepatitis B Vaccine (Recombinant), Adjuvanted.**

CC: Marian Major, Chair, BLA Review Committee, DBPAP/OVRR

Katherine Berkhausen, Lead RPM, DVRPA/ OVR

Richard Daemer, RPM, DVRPA/OVR

Sudhakar Agnihothram, RPM, DVRPA/OVR

Applicant: Dynavax Technologies Corporation

Product: Hepatitis B Vaccine (Recombinant), Adjuvanted

1. General Information

1.1 CMC Review Identifiers and Dates

1.1.1 Biologics License Application (BLA) Submission Tracking Number (STN) #: 125428

1.1.2 Submission received by CBER: Apr 26, 2012

1.1.3 Review completed: June 27, 2017

1.1.4 Material Reviewed

Original BLA: The following general module sections of the BLA were reviewed: M3 CMC, Quality

2. Executive Summary: The Lot Release Protocol Template submitted in amendment 125428/0.92 on June 21, 2017 is acceptable for use.

3. Review

3.1 Documents Reviewed

1. Lot Release Protocol Template submitted in amendment 125428/0.77 on 3/17/2017
2. Lot Release Protocol Template submitted in amendment 125428/0.85 on 5/10/2017
3. Lot Release Protocol Template submitted in amendment 125428/0.92 on 6/21/2017

3.2 Review

A lot release protocol template was included in the s amendment 125428/0.77) received by CBER on March 17, 2017.

The following comments were sent on May 03, 2017.

We are reviewing your submission for STN 125428 and have the following IR regarding the Lot Release Protocol Template submitted in 125428/0.77 on 17th March, 2017

1. On all pages please delete the top 2 lines (Dynavax Technologies Corporation BLA 125428/ SEQ No. 0075 and HEPLISAV™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] HEPLISAV Lot Release Protocol.
2. On pages 4 and 5 of 6 pages, Change the Endotoxin unit from EU/mL to IU/mL.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Dynavax addressed the comments for the Lot Release Protocol Template in amendment 125428/0.85 on 5/10/2017.

The following comments were sent on June 13, 2017.

We are reviewing your submission for STN 125428 and have the following request for information regarding the Lot Release Protocol Template submitted in 125428/0.85 on 10th May, 2017.

1. On all pages
 - a. Please move the Trade Name: Heplisav-B™ to a separate line below the Licensed Name of the product.
 - b. Delete the License Number: 1883 which is under the Licensed Name of the product.
2. Please submit an example of a Lot Release Protocol with actual results.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

A subsequent draft LRP template was submitted in amendment 125428/0.92 on June 21, 2017. Dynavax has addressed all CBER comments adequately.

3.3 Conclusions

The Lot Release Protocol Template submitted in amendment 125428/0.92 on June 21, 2017 is acceptable for use.